
NASDAQConsumer DefensiveHousehold & Personal Products
最新資料
US$7.00
−US$0.1056 · -1.49%
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
前收盤價
US$7.00
−US$0.1056 · -1.49%
盤中時間採用ET。市場資料可能有所延遲。
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
日內區間
目前US$7.00
52週區間
目前US$7.00
盤中時間採用ET。市場資料可能有所延遲。
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
日內區間
目前US$7.00
52週區間
目前US$7.00
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1054.55萬 USD | 1218.2萬 USD | 1088.52萬 USD | 1269.85萬 USD | 1392.96萬 USD |
| 銷貨成本 | 551.25萬 USD | 572.16萬 USD | 547.96萬 USD | 599.64萬 USD | 574.79萬 USD |
| 毛利 | 503.29萬 USD | 646.04萬 USD | 540.56萬 USD | 670.21萬 USD | 818.17萬 USD |
| 研究與開發 | 46.36萬 USD | 45.68萬 USD | 46.4萬 USD | 49.08萬 USD | 47.86萬 USD |
| 營業費用 | 278.96萬 USD | 281.36萬 USD | 254.26萬 USD | 266.49萬 USD | 251.46萬 USD |
| 利息收入 | 36.53萬 USD | 43.47萬 USD | 30.67萬 USD | 23.67萬 USD | 23.39萬 USD |
| 利息支出 | — | — | — | 161.91萬 USD | — |
| 折舊和攤銷 | 10.82萬 USD | 9.59萬 USD | 10.57萬 USD | 13.54萬 USD | 14.6萬 USD |
| 營業利益 | 224.33萬 USD | 364.68萬 USD | 286.3萬 USD | 403.72萬 USD | 566.71萬 USD |
| 淨利 | 210.57萬 USD | 325.09萬 USD | 258.14萬 USD | 256.95萬 USD | 465.85萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
年度分割調整後的每股現金分配。
US$0.60
2025年(完整年度)-23.1% 自從 2020
2026年(部分年度):US$0.55
US$0.78
2,020
US$1.13
2,021
US$0.68
2,022
US$0.60
2,024
US$0.60
2,025
US$0.55
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月28日 | US$0.30Semi-Annual | 2026年7月28日 | 2026年8月4日 |
股息 | 2026年2月9日 | US$0.25Semi-Annual | 2026年2月9日 | 2026年2月17日 |
股息 | 2025年7月25日 | US$0.25Semi-Annual | 2025年7月25日 | 2025年8月1日 |
股息 | 2025年2月10日 | US$0.35Semi-Annual | 2025年2月10日 | 2025年2月18日 |
股息 | 2024年7月23日 | US$0.35Semi-Annual | 2024年7月23日 | 2024年7月31日 |
股息 | 2024年2月9日 | US$0.25Semi-Annual | 2024年2月12日 | 2024年2月20日 |
除息 2026年7月28日
US$0.30
Semi-Annual
2026年7月28日登記 · 支付日 2026年8月4日
除息 2026年2月9日
US$0.25
Semi-Annual
2026年2月9日登記 · 支付日 2026年2月17日
除息 2025年7月25日
US$0.25
Semi-Annual
2025年7月25日登記 · 支付日 2025年8月1日
除息 2025年2月10日
US$0.35
Semi-Annual
2025年2月10日登記 · 支付日 2025年2月18日
除息 2024年7月23日
US$0.35
Semi-Annual
2024年7月23日登記 · 支付日 2024年7月31日
除息 2024年2月9日
US$0.25
Semi-Annual
2024年2月12日登記 · 支付日 2024年2月20日
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI65.35萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF26.07萬0.00%954億 USD0.05%US$235+0.80%
U.S. Micro Cap Portfolio ETFDFMC22.79萬0.00%75.58億 USD0.43%US$57.813+0.20%
Dimensional - US Small Cap ETFDFAS13.26萬0.00%338.69億 USD0.31%US$78.35+0.32%
iShares Micro-Cap ETFIWC7.47萬0.01%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM5萬0.05%1.17億 USD0.73%US$15.9402+0.25%
Dimensional - US Core Equity 2 ETFDFAC3.45萬0.00%885.96億 USD0.21%US$45.33+0.49%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.95萬0.00%455.91億 USD0.17%US$84.44+0.44%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
U.S. Micro Cap Portfolio ETFDFMC
Dimensional - US Small Cap ETFDFAS
iShares Micro-Cap ETFIWC
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM
Dimensional - US Core Equity 2 ETFDFAC
U.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。